The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism

International Journal of Cardiology
Prakash Deedwania

Abstract

Cardiometabolic risk factors affect more than 47 million adults in the United States today. Although certain risk factors (e.g., obesity, dyslipidemia, hypertension, and hyperglycemia) contribute independently to the global risk, dyslipidemia is one of the most important risk factors for cardiovascular disease. Successful treatment requires a well-coordinated multifaceted approach, with commitment to a long-term program for disease management. Although initial attempts should focus on dietary changes and increased physical activity, most patients also need effective, safe, and well-monitored pharmacotherapy. Experimental studies have shown that overactivation of the endocannabinoid system-a physiologic signaling system involved in regulating energy intake, fatty acid synthesis and storage, and glucose and lipid metabolism-is associated with obesity, dyslipidemia, and insulin resistance. In clinical trials, selective blockade of CB1 receptors has resulted in substantial weight loss and significant improvement in lipid profiles. The effects of rimonabant, the first selective CB1 receptor blocker, were evaluated in 6600 obese or overweight adults who participated in one of 4 multicenter, placebo-controlled, randomized clinical tri...Continue Reading

References

Aug 23, 2000·The Journal of Clinical Investigation·H N Ginsberg
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Aug 15, 2001·The Journal of Clinical Endocrinology and Metabolism·W S YangL M Chuang
Oct 26, 2002·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Christine Ravinet TrillouPhilippe Soubrie
Mar 12, 2003·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·D CotaU Pagotto
Apr 10, 2003·JAMA : the Journal of the American Medical Association·Dena M BravataDawn M Bravata
Feb 11, 2004·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·C Ravinet TrillouP Soubrié
Sep 24, 2004·Current Medical Research and Opinion·T P DidangelosD T Karamitsos
Jan 12, 2005·Diabetes, Obesity & Metabolism·B PoirierJ-M Herbert
May 3, 2005·The Journal of Clinical Investigation·Douglas Osei-HyiamanGeorge Kunos
Jul 13, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Omar JbiloPierre Casellas
Nov 10, 2005·The Clinical Biochemist. Reviews·Gisela Wilcox
Nov 18, 2005·The New England Journal of Medicine·Jean-Pierre DesprésUNKNOWN Rimonabant in Obesity-Lipids Study Group
Nov 25, 2005·Endocrine Reviews·Uberto PagottoRenato Pasquali
Jan 17, 2007·International Journal of Obesity : Journal of the International Association for the Study of Obesity·M CôtéV Di Marzo

❮ Previous
Next ❯

Citations

Apr 24, 2012·International Journal of Cardiology·Vitor Hugo PereiraNuno Sousa
Mar 25, 2009·Pharmacological Reports : PR·François MachSabine Steffens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.